comparemela.com
2
3
4
5
6
7
8
Latest Breaking News On - Tc markets quoted - Page 1 : comparemela.com
Anteris Technologies Ltd appoints highly experienced chief medical officer
The appointment of Dr Meduri, a recognised leader in the field of valvular heart disease, is expected to give further credibility to Anteris’ DurAVR™.
Anteri-dur
Wayne-paterson
Harvard-school-of-public-health
Beth-israel-deaconess-medical-center
Medicine-at-duke-university
Harvard-medical-school
Masters-in-public-health
Interventional-cardiologist
Advisory-board
Anteris-medical-advisory-board
Public-health
Clinical-effectiveness
Anteris Technologies Ltd extends manufacturing agreement with LeMaitre Vascular Inc for CardioCel™ and VascuCel™
Anteris Technologies is a structural heart company delivering clinically superior and durable solutions through better science and better design.
Australia
Wayne-paterson
Anteri-cardiocel
Lemaitre-vascular-inc
Maitre-vascular-inc
European-medical-devices-directorate
Small-caps
Tc-markets-quoted
Otcqb-quoted
Harma-biotech
Anteris-technologies-ltd
Sx-avr
NA Proactive news snapshot: Australis Capital, Mountain Valley MD Holdings Inc, Kwesst Micro Systems Inc, Todos Medical Ltd, Altiplano Metals Inc, RedHill Biopharma Ltd, Naturally Splendid Enterprises Ltd, NEO Battery Materials Ltd UPDATE ...
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires
Mexico
New-york
United-states
Greenland
Nevada
United-kingdom
Brazil
Vancouver
British-columbia
Canada
China
Redhill
Amarillo Gold reports financial results as financing for Posse Project continues
Amarillo Gold Corp CEO Mike Mutchler joined Steve Darling from Proactive to share the company’s financial results for the six months ended June 30,.
Mike-mutchler
Amarillo-gold-corp
Steve-darling
Posse-gold-project
Director-interviews
Small-caps
Ano-caps
Tc-markets-quoted
Otcqb-quoted
Gold-silver
Amarillo-gold-corporation
Cve-agc
Imugene Limited welcomes phase-1 trial dosing schedule for third monotherapy cohort of immunotherapy PD1-Vaxx
Clinical results continue to indicate that PD1-Vaxx is showing early signs of an immune response in patients, with antibodies to the target biomarker.
Australia
Australians
Leslie-chong
Cohort-review-committee
Small-caps
Tc-markets-quoted
Otcqb-quoted
Harma-biotech
Imugene-limited
Asx-imu
Roactiveinvestors
vimarsana © 2020. All Rights Reserved.